To Check the Safety and Effectiveness of Derma Goodness AcNil3 Acne Spot Corrector in the Reduction of Acne

A Clinical Study to Assess the Safety and Effectiveness of Derma Goodness AcNil3 Acne Spot Corrector in the Reduction of Acne - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/04/108186

Enrollment

Registered

2026-04-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: AcNil3 Acne Spot Corrector: Application: Direct application on acne lesions as per defined regimen, Route of Administration: Topical, Duration: 3Days Control Intervention1

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female, 18 45 years, able to give informed consent. 2. Mild to moderate acne vulgaris as defined above. 3. Minimum defined number of acne lesions 4. Willing to comply with study procedures and avoid new topical acne treatments during study. 5. Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 6. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 7. Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Use of systemic acne medications (e.g., oral isotretinoin within past 6 months) or topical prescription acne medications within 4 weeks. 2. Significant dermatologic conditions other than acne that could interfere with assessments. 3. Ongoing dermatological treatement. 4. Recent facial procedures (chemical peels, lasers) within 4 weeks. 5. Have participated in any interventional clinical trial in the previous 90 days. 6. Have a known sensitivity to any of the constituents of the test product 7. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids. 8. Have not skin related issues. 9.Severe acne or cystic acne.

Design outcomes

Primary

Measure	Time frame
1. Change in Sebum 2. Change in Acne counts 3. DSLR ImagingTimepoint: At Day 0, 1hr, Day 1, Day 3	—

Secondary

Measure	Time frame
Not ApplicableTimepoint: Not Applicable	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results